While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
Shelli Avenevoli, Ph.D., the deputy director for the National Institute of Mental Health (NIMH), joined Cheddar to discuss concerns about the devastating impact the pandemic has had on the nation's youth. While mental health issues have been a point of concern for the populace at large, Avenevoli talked about how vulnerable young people have been during the COVID-19 crisis. "It's important to keep in mind, for children and adolescents, that the pandemic is occurring during a time of very formative development when social connection is vital for health and optimal function," she said. Avenevoli also noted broad political and social upheavals that have contributed to the issue but also things that can be done to help minors with their mental wellbeing.
Cheddar Innovates gets a look at the satellite that's searching for the earliest light from the big bang, plus a former Nike executive breaks down what the new era of sportswear looks like.
A packed Thursday pod: Carlo and Baker cover the latest developments in the Ghislaine Maxwell, Jussie Smollett and Elizabeth Holmes trials. Plus, Dems are losing the Hispanic vote, Boris Johnson in trouble again, and is it possible that Adele has peaked?
Adam Mosseri, head of Instagram, faced withering questions on Capitol Hill about the reports the social media app was aware of the severe mental health impacts it was having on teenage girls. Karen Kornbluh, the director of digital innovation and democracy for the German Marshall Fund, joined Cheddar to discuss the rare show of bipartisan outrage on display at the Senate hearing. "The senators came really loaded for bear on both sides of the aisle," she said. Kornbluh explained how senators like Richard Blumenthal (D-Conn.) set up fake Instagram accounts with teen girl profiles in order to research the effects firsthand.
A mental health crisis among young people is looming, and a large part of it is online. Cheddar News speaks with digital policy expert Karen Kornbluh on the issue.
Back in 2010, several large companies pledged to work towards stopping deforestation by 2020. Companies like Nestle and Carrefour even went further to say that they would eliminate deforestation from their supply chains altogether. However, fast forward to 2020, many of these companies have failed to reach that goal. Associate Director of Forest at the CDP Nadia Bishai, joined Cheddar to discuss more.
A new study by Pfizer-BioNTech found that a third dose of their COVID-19 vaccine is effective against the emerging omicron variant. The pharmaceutical giants also look to manufacture a vaccine specific to the omicron variant by March 2022.
